|
|
|
|
|
|
|
|
abstract
Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy - Annual Review of Medicine, 68(1)
The tools
of next-generation sequencing (NGS) technology, such as targeted
sequencing of candidate cancer genes and whole-exome and -genome
sequencing, coupled with encouraging clinical results based on the use
of targeted therapeutics and biomarker-guided clinical trials, are
fueling further technological advancements of NGS technology. However,
NGS data interpretation is associated with challenges that must be
overcome to promote the techniques’ effective integration into clinical
oncology practice. Specifically, sequencing of a patient’s tumor yields
30–65 somatic variants, but most of these variants are “passenger”
mutations that are phenotypically neutral and thus not targetable.
Therefore, NGS data must be interpreted by multidisciplinary
decision-support teams to determine mutation actionability and identify
potential “drivers,” so that the treating physician can prioritize what
clinical decisions can be pursued in order to provide cancer therapy
that is personalized to the patient and his or her unique genome.
Expected final online publication date for the Annual Review of Medicine Volume 68 is January 14, 2017. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.
Expected final online publication date for the Annual Review of Medicine Volume 68 is January 14, 2017. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.